Clinical trial
Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With…
NCT00003962 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00003962 |
|---|---|
| Title | Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer |
| Official title | Dose Finding Study of Toxicity and Immunomodulatory Effects of Interleukin-2 Following Allogeneic Bone Marrow Transplantation in Patients at High Risk for Relapse |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological |
| Interventions | aldesleukin |
| Start date | Apr 1, 1998 |
| Primary completion | Jun 1, 2000 |
| Completion | Jun 1, 2000 |
| First posted | Aug 27, 2004 |
| Last update posted | May 2, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: